Financial reports
10-K
2023 FY
Annual report
29 Feb 24
10-Q
2023 Q3
Quarterly report
13 Nov 23
10-Q
2023 Q2
Quarterly report
10 Aug 23
10-Q
2023 Q1
Quarterly report
8 May 23
ARS
2022 FY
Annual report to shareholders
28 Apr 23
10-K
2022 FY
Annual report
30 Mar 23
10-Q
2022 Q3
Quarterly report
7 Nov 22
10-Q
2021 Q3
Quarterly report
8 Aug 22
10-Q
2022 Q1
Quarterly report
9 May 22
10-K
2021 FY
Annual report
1 Mar 22
Current reports
8-K
Y-mAbs Therapeutics Announces Resignation of Chief Financial Officer
14 Mar 24
8-K
Y-mAbs Appoints Oncology Executive Mary Tagliaferri, M.D. to its Board of Directors
4 Mar 24
8-K
Y-mAbs Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Corporate Developments
29 Feb 24
8-K
Results of Operations and Financial Condition
9 Jan 24
8-K
Y-mAbs Reports Third Quarter 2023 Financial Results and Recent Corporate Developments
13 Nov 23
8-K
Y-mAbs Names Michael Rossi as President and Chief Executive Officer and Director
18 Oct 23
8-K
Y-mAbs Therapeutics Announces U.S. FDA Clearance of Investigational New Drug Application for CD38-SADA
18 Oct 23
8-K
Y-mAbs Reports Second Quarter 2023 Financial Results and Recent Corporate Developments
10 Aug 23
8-K
Submission of Matters to a Vote of Security Holders
9 Jun 23
8-K
Y-mAbs Announces Presentation of Naxitamab Data at ASCO
26 May 23
Registration and prospectus
S-8
Registration of securities for employees
29 Feb 24
S-8
Registration of securities for employees
30 Mar 23
S-3
Shelf registration
30 Mar 23
424B5
Prospectus supplement for primary offering
18 Feb 21
424B5
Prospectus supplement for primary offering
17 Feb 21
424B5
Prospectus supplement for primary offering
31 Oct 19
424B5
Prospectus supplement for primary offering
30 Oct 19
S-3
Shelf registration
1 Oct 19
S-8
Registration of securities for employees
22 Mar 19
424B4
Prospectus supplement with pricing info
21 Sep 18
Proxies
DEFA14A
Additional proxy soliciting materials
28 Apr 23
DEF 14A
Definitive proxy
28 Apr 23
DEFA14A
Additional proxy soliciting materials
29 Apr 22
DEF 14A
Definitive proxy
29 Apr 22
DEFA14A
Additional proxy soliciting materials
28 Apr 21
DEF 14A
Definitive proxy
28 Apr 21
DEF 14A
Definitive proxy
28 Apr 20
DEFA14A
Additional proxy soliciting materials
28 Apr 20
DEF 14A
Definitive proxy
30 Apr 19
Other
EFFECT
Notice of effectiveness
8 May 23
CORRESP
Correspondence with SEC
2 May 23
UPLOAD
Letter from SEC
3 Apr 23
SEC STAFF
SEC staff action: Order
28 Feb 20
SEC STAFF
SEC staff action: Order
6 Feb 20
EFFECT
Notice of effectiveness
16 Oct 19
CORRESP
Correspondence with SEC
10 Oct 19
UPLOAD
Letter from SEC
7 Oct 19
CT ORDER
Confidential treatment order
1 Oct 18
EFFECT
Notice of effectiveness
21 Sep 18
Ownership
SC 13G
Paradigm Biocapital Advisors LP
8 Apr 24
4
MARY TAGLIAFERRI
14 Mar 24
3
MARY TAGLIAFERRI
8 Mar 24
4
Vignesh Rajah
7 Mar 24
4
Thomas Gad
7 Mar 24
4
Susan Laura Smith
7 Mar 24
144
Notice of proposed sale of securities
6 Mar 24
144
Notice of proposed sale of securities
6 Mar 24
144
Notice of proposed sale of securities
5 Mar 24
4
Michael J Rossi
14 Feb 24